Catalyst
Slingshot members are tracking this event:
BioPharmX Corporation (BPMX) aiming to begin phase 2/3 pivotal trial on BPX-01 for treating rosacea, in third quarter of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BPMX | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 12, 2017
Occurred Source:
http://biopharmx.investorroom.com/2017-09-12-BioPharmX-Announces-Preliminary-Data-from-Rosacea-Feasibility-Study
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rosacea, Phase 2/3 Study
